Biote Corp.
NNASDAQ:BTMDCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert C. Peterson
- Full Time Employees
- 223
- Sector
- Health services
- Industry
- Hospital/Nursing management
- Address
- 1875 West Walnut Hill Lane Irving TX United States 75038
- IPO Date
- Mar 2, 2021
- CIK
- 0001819253
- Website
- biote.com
- Similar Companies
- Business
- biote Corp. operates a growth-focused medical practice-building enterprise within the expansive hormone optimization and therapeutic wellness industry. The company furnishes a comprehensive, integrated platform, known as the Biote Method, empowering its certified medical providers to develop and manage programs designed to balance patient hormone, vitamin, and mineral levels. This offering includes specialized education, training, and certification in bioidentical hormone therapies, alongside advanced practice and inventory management software, and digital marketing tools. biote also markets its proprietary line of dietary supplements and sterile kits for hormone pellet insertions. Serving a broad population of American men and women experiencing hormonal imbalances, the company enhances its supply chain efficiency through vertical integration, notably with the 2024 acquisition of Asteria Health. Founded in 2012, biote Corp. is based in Irving, Texas.
Company News
biote Corp. (BTMD) Q3 2026 Earnings Call Transcript
biote Corp. (BTMD) Tops Q3 Earnings Estimates
Biote Reports Third Quarter 2026 Financial Results
Head-To-Head Survey: The Pennant Group (NASDAQ:PNTG) vs. biote (NASDAQ:BTMD)
Biote Schedules Third Quarter 2026 Financial Results Release and Conference Call
biote (NASDAQ:BTMD) and Elevance Health (NYSE:ELV) Head to Head Review
biote Corp. (BTMD) Q2 2026 Earnings Call Transcript
biote Corp. (BTMD) Reports Break-Even Earnings for Q2
biote Q2 Earnings Call Highlights
Biote Reports Second Quarter 2026 Financial Results
Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call
Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer
Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
biote Corp. (BTMD) Q1 2026 Earnings Call Transcript
biote Corp. (BTMD) Q1 Earnings and Revenues Lag Estimates
Biote Reports First Quarter 2026 Financial Results
Biote Schedules First Quarter 2026 Financial Results Release and Conference Call
biote Corp. (BTMD) Q4 2025 Earnings Call Transcript
biote Corp. (BTMD) Q4 Earnings and Revenues Top Estimates